GPT and fatty liver disease: Significant reduction in hepatic steatosis (mean decrease in CAP score −53.76 dB/m [95% CI −73.04 to −34.47), NAFLD activity score (evaluated in 2 studies, mean decrease −3 [95% CI −3.27 to −2.73]) and HOMA-IR levels were seen, as well as decrease in ALT (mean decrease −12.44 U/L [95% CI −14.70 to −10.19]), AST (mean decrease −7.88 U/L [95% CI −11.11 to −4.64]), GGT (−12.07 U/L [95% CI −15.79 to −8.35]), triglyceride, total cholesterol levels and total body weight.